Analyst consensus rating
BridgeBio Pharma Analyst Rating: Strong Buy
BBIO is rated Strong Buy by 21 analysts with a $108.43 target. As of 2026-08-15.
Direct answer
BridgeBio Pharma's consensus rating is Strong Buy.
21 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $108.43.
Forecast evidence checked August 15, 2026.
Get free BridgeBio Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $79.86
- Average price target
- $108.43
- High price target
- $157.00
- Low price target
- $80.00
- Low target gap
- +0.2%
- Target upside
- +35.8%
- High target gap
- +96.6%
- Target range width
- 96.4%
- Consensus rating
- Strong Buy
- Analysts
- 21
- Evidence date
- August 15, 2026
- Valid through
- August 22, 2026